Alexion wants to return Zealand Pharma candidate
Contrary to expectations, there are no indications that Zealand Pharma will develop the preclinical candidate ZP10068 for complement-mediated diseases alongside American Alexion Pharmaceuticals.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.